Source and scope
This summary is bounded to the recommendations, population and decisions covered by No. 292: Abnormal Uterine Bleeding in Pre-Menopausal Women. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC 292
Source-attributed clinical priorities
- Assess bleeding pattern, anemia, pregnancy possibility, medication and bleeding-disorder risk, and structural or malignant features.
- Use examination, blood work and imaging selectively according to age, symptoms and risk rather than as a fixed panel for everyone.
- Match medical or procedural treatment to cause, fertility goals, contraindications and patient preference, escalating hemodynamic instability urgently.
- Quantify impact on life and iron status rather than relying only on an estimated volume of blood loss.
sources for this section:SOGC 292
Practical assessment and management workflow
1
Confirm pregnancy status and describe cycle regularity, intermenstrual or postcoital bleeding, pain and bleeding disorder clues.
2
Examine when structural disease is possible and obtain blood count and targeted imaging or sampling.
3
Select medical treatment by contraception needs, fibroid or adenomyosis features, contraindications and preference.
4
Review bleeding, hemoglobin, adverse effects and the need for procedural or gynecology referral.
sources for this section:SOGC 292
Safety, red flags and urgent escalation
- Hemodynamic instability, syncope or symptomatic severe anemia requires urgent treatment.
- Investigate new postmenopausal, persistent intermenstrual or concerning postcoital bleeding promptly.
- Do not insert an intrauterine system until pregnancy and relevant uterine or infectious contraindications are considered.
sources for this section:SOGC 292
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC 292
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC 292
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Society of Obstetricians and Gynaecologists of CanadaNo. 292: Abnormal Uterine Bleeding in Pre-Menopausal WomenDOI 10.1016/j.jogc.2018.03.007 · J Obstet Gynaecol Can 2018;40(5):e391-e415 · accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.